Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT versus KENALOG IN ORABASE.
FLOVENT vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a synthetic corticosteroid with anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory transcription factors (e.g., NF-κB) and increased synthesis of lipocortin-1, which reduces phospholipase A2 activity and subsequent release of arachidonic acid metabolites (prostaglandins, leukotrienes). In the lungs, it decreases airway inflammation by reducing eosinophil infiltration, mast cell degranulation, and cytokine release.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Inhalation aerosol: 88-880 mcg twice daily; typical starting dose: 88 mcg twice daily. Max: 880 mcg twice daily. Oral inhalation powder: 100-1000 mcg twice daily; typical starting: 100 mcg twice daily. Max: 1000 mcg twice daily.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
Approximately 14.4 hours (range 7.8–24.6 hours) for the inhaled route; supports twice-daily dosing; prolonged in hepatic impairment.
Terminal half-life approximately 2-5 hours following mucosal application.
Primarily hepatic metabolism (CYP3A4) with fecal excretion of metabolites; renal excretion accounts for <5% of the dose as unchanged drug and metabolites combined.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category C
Category C
Corticosteroid
Corticosteroid